Eloxx Pharmaceuticals, Inc.
corporate_fare Company Profile
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for ELOX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ELOX spans 8-K, 10-Q, 4, S-1/A.
Recent high-impact activity:
- Eloxx Posts Smaller-Than-Expected Q3 Loss of 49 Cents a Share
- FDA Clears Eloxx IND for Exaluren in ADPKD; First Dosing Set for 3Q 2027
- Eloxx Posts $4.5M Q2 Loss, $62M Cash; Phase 2b Alport Trial Set for Q3
- Eloxx Q2 Loss Widens to $4.5M; Cash Runway Extended to Mid-2028 After $66M Raise
- Eloxx Posts $8.3M Net Loss, Flags Material Weakness; Cash Runway Extended Through June 2027
Short Interest & Short Volume
2.07 days to coverFINRA reported short interest of 52,603 shares in ELOX as of the October 30, 2026 settlement, a 27.2% increase from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 47.0% of ELOX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ELOX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-01.
Critical Capital Raise Announced · Premium Offering Price
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →